Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;92(6):540-545.
doi: 10.1002/jmv.25733. Epub 2020 Mar 5.

Clinical trial analysis of 2019-nCoV therapy registered in China

Qi Zhang  1 , Yakun Wang  1 , Changsong Qi  1 , Lin Shen  1 , Jian Li  1
Affiliations
Review

Clinical trial analysis of 2019-nCoV therapy registered in China

Qi Zhang et al. J Med Virol. 2020 Jun.

Abstract

So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.

Keywords: China; clinical trial; new coronavirus pneumonia; new drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
The location distribution for clinical trial of 2019‐nCoV. nCoV, novel coronavirus
Figure 2
Figure 2
The classification of experimental drugs for 2019‐nCoV. nCoV, novel coronavirus
See this image and copyright information in PMC

Comment in

References

    1. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019‐nCoV). Radiology. 2020:200230. - PMC - PubMed
    1. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019‐nCoV) by real‐time RT‐PCR. Euro Surveill. 2020;25(3):2000045. - PMC - PubMed
    1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS‐CoV‐2 infection: a nationwide analysis in China. Lancet Oncol. 2020;S1470‐2045(1420):30096. - PMC - PubMed
    1. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLOS Med. 2006;3(9):e343. - PMC - PubMed
    1. Shen L, Niu J, Wang C, et al. High‐throughput screening and identification of potent broad‐spectrum inhibitors of coronaviruses. J Virol. 2019;93(12):e00023‐00019. - PMC - PubMed

MeSH terms